PDCD1 and neoplasm: At present, the descriptions of related biomarkers in the indications of PD-1/PD-L1 inhibitors are only as follows: “pembrolizumab for advanced/recurrent non-small cell lung cancers [It may be use monotherapy if tumor tests positive for PD-L1.